Coronary Artery Disease.
Conditions
Interventions
Intervention 1: Intervention group:. Intervention 2: Control group:.
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 65 Years
Inclusion criteria
Inclusion criteria: age between 65-40 years BMI between 25-35 Proof of 50% stenosis in at least one of the major coronary arteries in angiography Ability, and willingness to collaborate on the project
Exclusion criteria
Exclusion criteria: Smoking, alcohol and hookah consumption Hypothyroidism and Hyperthyroidism Uncontrolled diabetes History of myocardial infarction Cardiac dysfunction (Class 3 and 4) Valvular heart disease Kidney failure Pregnant and lactating women Taking herbal supplements and antioxidants in the last three months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum level of Sirtuin1. Timepoint: At the beginning and end of the study after 8 weeks. Method of measurement: Measurement with ELISA kit.;Serum level TNF-?. Timepoint: At the beginning and end of the study after 8 weeks. Method of measurement: Measurement with ELISA kit.;Lipid profile. Timepoint: At the beginning and end of the study after 8 weeks. Method of measurement: Enzyme kits and the Friedwald equation.;Glycemic indexes. Timepoint: At the beginning and end of the study after 8 weeks. Method of measurement: ELISA and spectrophotometer.;Anthropometric Indices. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Measurement of height and weight without shoes and with minimum clothes on, by Seca stadiometer and scale, respectively. Measurement of the waist and hip circumference by a tape measure and body mass index (BMI) by dividing weight (kg) by height squared (m2) and measurement of body composition.;Oxidative stress indices. Timepoint: At the beginning and end of the study after 8 weeks. Method of measurement: Measurement of serum levels of Total antioxidant capacity (TAC) and malondialdehyde (MDA) and Superoxide dismutase by spectrophotometry.;Plasminogen activator inhibitor-1. Timepoint: At the beginning and end of the study after 8 weeks. Method of measurement: Measurement with ELISA kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Physical activity level. Timepoint: At the begening and end of the intervention. Method of measurement: Via IPAQ questionnaire.;Quality of life. Timepoint: At the beginning and end of the study after 8 weeks. Method of measurement: Via MacNew questionnaire.;Depression severity. Timepoint: At the beginning and end of the study after 8 weeks. Method of measurement: Beck Depression Inventory scale.;Blood pressure. Timepoint: At the beginning and end of the study after 8 weeks. Method of measurement: Using a mercury barometer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarzieh heidari
Tabriz University of Medical Sciences
Outcome results
None listed